Ilumya™ (tildrakizumab-asmn)

Ilumya (tildrakizumab-asmn) is covered only for adults (≥18) with FDA‑approved moderate‑to‑severe plaque psoriasis and is excluded for non‑FDA indications and patients under 18. Initial approval requires prescription by or consultation with a dermatologist and a 3‑month trial (or intolerance) of ≥1 biologic or traditional systemic agent (or contraindication to methotrexate); reauthorization requires ≥90 days on Ilumya with documented improvement in ≥1 objective sign (BSA, erythema, induration/thickness, or scale) and ≥1 symptom (eg, pain, itching, burning), dosing per label (100 mg SC at weeks 0, 4, then every 12 weeks), and approvals are limited to 12 months.

"Initial authorization alternative: Patient has a contraindication to methotrexate therapy."

Sign up to see full coverage criteria, indications, and limitations.